Yposkesi
Top SEO sites provided "Yposkesi" keyword
GenSight Biologics – Leader in Gene Therapy Against Blindness
#gensite
#muna therapeutics
#axxam spa
#buy tramadol
#tramadol online
#genethon
#yposkesi
#pcr définition
#cost forecasting
#best practices template
#financial tracking
#enterprise portfolio management
#genesight login
#genesight
#genesight clinician portal
#mygenesight
#genesight testing
Keyword Suggestion
Related websites
The story and experts of the biggest european's CDMO
WEByposkesi is a trusted partner for biotechs and pharma seeking to advance and commercialize new ATMPs. It offers a full range of services in lentiviral vectors and AAV cGMP manufacturing, with a state-of-the-art facility in …
Yposkesi.comYposkesi's platforms CDMO | Yposkesi - Yposkesi
WEBAt yposkesi, we have more than 30 years of experience in viral vector manufacturing and two platforms for AAVs and lentiviral vectors. To produce cell and gene therapies, drug …
Yposkesi.comWith $71M investment, French CDMO Yposkesi set to …
WEBJun 15, 2021 · Boosted by investment in March from new majority equity shareholder SK Holdings, yposkesi will pour $71 million into the 50,000 square foot site. The investment …
Fiercepharma.comMedia Center | SK Inc.
WEBJun 23, 2023 · yposkesi's second bioproduction site is situated in its Genopole campus, the largest biotech cluster in France. The newly completed site is a 5,000 m2 facility …
Sk-inc.comSK pharmteco doubles viral vector production capacity in …
WEBJun 22, 2023 · yposkesi, SK pharmteco's clinical and commercial viral vector manufacturing subsidiary for Cell and Gene Therapy (C>), completes its second bioproduction facility and doubles its manufacturing
Prnewswire.comSK pharmteco Expands into Cell and Gene Therapy With the …
WEBApr 28, 2021 · yposkesi is a leading CDMO focusing on producing gene therapy drugs with one of the largest GMP manufacturing facilities in Europe of lentiviral and AAV vectors.
Skpharmteco.comYposkesi is on a roll: CDMO’s expanded facility to be …
WEBNov 28, 2022 · yposkesi is on a roll: CDMO’s expanded facility to be operational in early 2024. yposkesi, an SK pharmteco company, has been witnessing a marked uptick in cell and gene therapy projects and has …
Biopharma-reporter.comYposkesi Breaks Ground for Second Plant - SK …
WEBJun 14, 2021 · yposkesi is investing $71 million to double its production space in its existing facility near Paris to 10,000 square meters, which would become one of the largest advance therapy medicinal products facilities …
Skpharmteco.comYposkesi’s New Facility to Support Viral Vector Demand
WEBJun 23, 2021 · French contract manufacturer yposkesi, which specializes in cell and gene therapies, has begun construction on the company’s second commercial facility for developers of advanced biologics.
Genengnews.comYposkesi begins construction of second cell and gene …
WEBJun 17, 2021 · yposkesi, a French contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, announced that it would commence building a second facility focused on …
Biopharma-reporter.comLeading innovation to industrial production of gene therapy
WEBLarge-scale manufacturing of viral vectors in a cost-efficient manner is certainly one of the key challenges that the bioproduction of gene therapy products is facing today. …
Yposkesi.comSK pharmteco Doubles Viral Vector Production Capacity in Europe
WEBJun 26, 2023 · yposkesi, SK pharmteco’s commercial viral vector manufacturing subsidiary in France, completed construction of its second industrial bioproduction site for cell and …
Genengnews.comYposkesi leveraging expertise of major shareholder, new facility …
WEBJan 25, 2022 · yposkesi leveraging expertise of major shareholder, new facility build on schedule. News & Analysis on the Clinical Development and Manufacture of Large …
Biopharma-reporter.comCreation of YposKesi - Généthon
WEBNov 3, 2016 · AFM-Téléthon and the SPI fund, managed by Bpifrance under the Programme d’Investissement d’Avenir, are creating yposkesi, the first French industrial …
Genethon.com| Yposkesi: Pushing the Boundaries of Gene Therapy-2020
WEByposkesi utilises cutting-edge technology to produce the viral vectors capable of delivering the high performance required by pharma companies. The company supports …
Pharmatechoutlook.comLentisure™: Yposkesi's lentiviral manufacturing platform
WEBLentiSure is optimized to deliver high-quality lentiviral vectors in a productive and scalable manner. Produced with yposkesi’s LentiSure platform, lentivirus yields at harvest are …
Yposkesi.comYposkesi, an SK pharmteco company | LinkedIn
WEByposkesi, an SK pharmteco company, is one of Europe’s largest Contract Development and Manufacturing Organizations (CDMO) for gene therapy viral vector manufacturing.
Linkedin.comSK Inc. acquires French bio pharm CDMO firm Yposkesi
WEBMar 31, 2021 · The deal to acquire a controlling stake in France-based yposkesi opens the door for SK to join the rapidly growing market for contract manufacturing of biologic …
Koreajoongangdaily.joins.comYposkesi launches lentiviral vector production platform optimised …
WEBApr 5, 2023 · yposkesi, SK pharmteco’s clinical and commercial viral vector manufacturing arm for cell and gene therapies, has announced the launch of LentiSure (trademarked), …
Manufacturingchemist.comNews related to Yposkesi's Cell & Gene therapy | Yposkesi
WEBLearn more about the news related to yposkesi's evolution within the Cell & Gene therapy field.
Yposkesi.comYposkesi, an SK pharmteco company (@yposkesi) / Twitter
WEBApr 16, 2018 · yposkesi, an SK pharmteco company, is one of Europe's largest CDMO's for clinical and commercial viral vector manufacturing #genetherapy #raredisease #AAV.
Twitter.comContact us to learn more about CDMO services | Yposkesi
WEBContact yposkesi to learn more about our CDMO services: AAV and lentiviral vector manufacturing for your cell & gene therapy products.
Yposkesi.com